$STX

Morris John Christopher sold $137K of STX

Morris John Christopher (EVP & CTO) sold 168 shares of Seagate Technology Holdings plc (STX) at $817.76 ($0.14M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Morris John Christopher
Published Aug 4, 2026, 10:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
high confidence
Mentioned
$STX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

Because the transaction is explicitly pre-arranged and small in dollar terms, it is unlikely to change Seagate’s near-term fundamentals based on this text alone.

02

Market read

Traders may log the insider sale for sentiment tracking, but the filing does not introduce a new operational or financial catalyst.

03

What to watch

The article does not state whether this sale is part of a larger series, nor does it include options activity or purchases that could offset net selling.

Relevance 3/10Novelty 2/10Timing: Form 4 filed 2026-08-04 after-hours

Background

The filing is an SEC Form 4 insider transaction for Seagate Technology Holdings plc, reported as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralHigh confidence
Context

Seagate CTO sold 168 shares in an open-market transaction at $817.76/share under a pre-arranged 10b5-1 plan, per Form 4 filed today.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction would be short-lived and sentiment-driven.

Evidence & confidence

The disclosure is a small, pre-arranged 10b5-1 sale by an officer, with no accompanying guidance, deal, or regulatory action in the text.

Market effects

No sector read-through is provided beyond a routine insider transaction.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private information, so traders may still watch for follow-on filings or unusual volume.

Key entities

  • Seagate Technology Holdings plc

    Subject of the Form 4 insider transaction disclosure.

  • Morris John Christopher

    EVP and CTO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.